Replicel Life Sciences Inc. (REPCF) SEC Filing 6-K Foreign Issuer report for the period ending Tuesday, March 5, 2019

Replicel Life Sciences Inc.

CIK: 1205059 Ticker: REPCF

View differences made from one to another to evaluate Replicel Life Sciences Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 6-K Foreign Issuer Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Replicel Life Sciences Inc..


Assess how Replicel Life Sciences Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Replicel Life Sciences Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2019 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Replicel Life Sciences Inc. provided additional information to their SEC Filing as exhibits

Ticker: REPCF
CIK: 1205059
Form Type: 6-K Foreign Issuer Report
Accession Number: 0001085037-19-000019
Submitted to the SEC: Wed Mar 06 2019 4:53:55 PM EST
Accepted by the SEC: Wed Mar 06 2019
Period: Tuesday, March 5, 2019
Industry: Gold And Silver Ores

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: